Advances and research directions in the prevention of mother-to-child HIV-1 transmission

Lancet

Volumn 355, Issue 9222, 2000, Pages 2237-2244

  Mofenson, Lynne M ^a   McIntyre, James A ^b  

^a EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^b UNIVERSITY OF THE WITWATERSRAND   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT;

ARTIFICIAL MILK; BREAST FEEDING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT NUTRITION; MEDICAL RESEARCH; PARENT COUNSELING; PRENATAL CARE; PRENATAL EXPOSURE; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; VERTICAL TRANSMISSION;

EID: 0034709711     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(00)02415-6     Document Type: Review

References (52)

1. AIDS epidemic update: December 1999. 1999;UNAIDS, Geneva. (available online at www.unaids.org/publications/documents/epidemiology/surveillance/wad1999/embaee. pdf ).
2. Connor E.M., Sperling R.S., Gelber R.et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. N Engl J Med. 331:1994;1173-1180.
3. Wade N.A., Birkhead G.S., Warren B.L.et al. Abbreviated regimens of zidovudine prophylaxis and perinatal transmission of the human immunodeficiency virus. N Engl J Med. 339:1998;1409-1414.
4. Elective caesarean-section versus vaginal delivery in prevention of vertical HIV-1 transmission: a randomised clinical trial. Lancet. 353:1999;1035-1039.
5. The mode of delivery and the risk of vertical transmission of human immunodeficiency virus type 1: a meta-analysis of 15 prospective cohort studies. N Engl J Med. 340:1999;977-987.
6. Women and Infants Transmission Study Investigators. Trends in mother-to-infant transmission of HIV in the WITS cohort: impact of 076 and HAART therapy. 2nd Conference on Global Strategies for the Prevention of HIV Transmission from Mothers to Infants. Montreal, September, 1999 (abstr 212).
7. Shaffer N., Chuachoowong R., Mock P.A.et al. Short-course zidovudine for perinatal HIV-1 transmission in Bangkok, Thailand: a randomised controlled trial. Lancet. 353:1999;773-780.
8. Wiktor S.Z., Ekpini E., Karon J.M.et al. Short-course zidovudine for prevention of mother-to-child transmission of HIV-1 in Abidjan, Côte d'Ivoire: a randomised trial. Lancet. 353:1999;781-785.
9. Dabis F., Msellati P., Meda N.et al. 6-month efficacy, tolerance and acceptability of a short regimen of oral zidovudine to reduce vertical transmission of HIV in breastfed children in Côte d'Ivoire and Burkina Faso: a double-blind placebo-controlled multicentre trial. Lancet. 353:1999;786-792.
10. 15-month efficacy of maternal oral zidovudine to decrease vertical transmission of HIV-1 in breastfed African children. Lancet. 354:1999;2050-2051.
11. Saba J, on behalf of the PETRA Trial Study Team. Interim analysis of early efficacy of three short ZDV/3TC combination regimens to prevent mother-to-child transmission of HIV-1: the PETRA Trial. 6th Conference on Retroviruses and Opportunistic Infections. Chicago, January-February, 1999 (abstr 57).
12. Guay L.A., Musoke P., Fleming T.et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. Lancet. 354:1999;795-802.
13. Lallemont M, Jourdain G, Soyeon K, et al. Perinatal HIV Prevention Trial (PHPT), Thailand: DSMB recommends termination of short-short arm after first interim analysis. 2nd Conference on Global Strategies for the Prevention of HIV Transmission from Mothers to Infants. Montreal, September, 1999 (abstr 016).
14. Jackson J.B., Becker-Pergola G., Guay L.A.et al. Identification of the K103N resistance mutation in Ugandan women receiving nevirapine to prevent HIV-1 vertical transmission. AIDS. 2000;. (in press).
15. Public Health Service Task Force recommendations for the use of antiretroviral drugs in pregnant women infected with HIV-1 for maternal health and for reducing perinatal HIV-1 transmission in the United States. MMWR Morb Mortal Wkly Rep. 47(RR-2):1998;1-30. (available online at www.hivatis.org ).
16. Wade N.A., Birkhead G.S., French P.T. Short courses of zidovudine and perinatal transmission of HIV. N Engl J Med. 340:1999;1042-1043.
17. Van Rompay K.K.A., Marthas M.L., Lifson J.D.et al. Administration of R-9(2-phosphonylmethoxypropyl) adenine (PMPA) for prevention of perinatal simian immunodeficiency virus infection in rhesus macaques. AIDS Res Hum Retroviruses. 14:1998;761-773.
18. Brinkman K., Ter Hofstede H.J.M., Burger D.M.et al. Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as a common pathway. AIDS. 12:1998;1735-1744.
19. Cherry M. AZT critics "swayed South African president" Nature. 402:1999;225.
20. Is zidovudine therapy in pregnant HIV-infected women associated with gestational age and birthweight? AIDS. 13:1998;119-124.
21. Culnane M., Fowler M.G., Lee S.S.et al. Lack of long-term effects of in utero exposure to zidovudine among uninfected children born to HIV-infected women. JAMA. 281:1999;151-157.
22. Hanson I.C., Antonelli T.A., Sperling R.S.et al. Lack of tumors in infants with perinatal HIV type 1 exposure and fetal/neonatal exposure to zidovudine. J Acquir Immune Defic Syndr. 20:1999;463-467.
23. Lorenzi P., Spicher V.M., Laubereau B.et al. Antiretroviral therapies in pregnancy: maternal, fetal and neonatal effects. AIDS. 12:1998;F241-F247.
24. Shapiro D, Tuomala R, Samelson R, et al. Antepartum antiretroviral therapy and pregnancy outcomes in 462 HIV-infected women in 1998-1999 (PACTG 367). 7th Conference on Retroviruses and Opportunistic Infections. San Francisco, January-February, 2000 (abstr 664).
25. Blanche S., Tardieu M., Rustin P.et al. Persistent mitochondrial dysfunction and perinatal exposure to antiretroviral nucleoside analogues. Lancet. 354:1999;1084-1089.
26. Smith, ME. US Nucleoside Safety Review Working Group. Ongoing nucleoside safety review of HIV-exposed children in US studies. 2nd Conference on Global Strategies for Prevention of HIV Transmission from Mothers to Infants. Montreal, September, 1999 (abstr 096).
27. Bulterys M., Nesheim S., Abrams E.et al. Lack of evidence of mitochondrial dysfunction in the offspring of HIV-infected women: retrospective review of perinatal exposure to antiretroviral drugs in the Perinatal AIDS Collaborative Study. Ann NY Acad Sci. 2000;. (in press).
28. Lange J, Stellato R, Brinkman K, et al. Review of neurologic adverse events in relation to mitochondrial dysfunction in the prevention of mother to child transmission of HIV: the PETRA study. 2nd Conference on Global Strategies for Prevention of HIV Transmission from Mothers to Infants. Montreal, September, 1999 (abstr 250).
29. Taha T.E., Biggar R.J., Broadhead R.L.et al. Effect of cleansing the birth canal with antiseptic solution on maternal and newborn morbidity and mortality in Malawi: clinical trial. BMJ. 315:1997;216-219.
30. Msellati P., Meda N., Leroy V.et al. Safety and acceptability of vaginal disinfection with benzalkonium chloride in HIV-infected pregnant women in west Africa: ANRS 049b phase II randomised, double blinded placebo controlled trial. Sex Transm Infect. 75:1999;420-425.
31. Coutsoudis A., Pillay K., Spooner E.et al. Randomized trial testing the effect of vitamin A supplementation on pregnancy outcomes and early mother-to-child HIV-1 transmission in Durban, South Africa. AIDS. 13:1999;1517-1524.
32. Semba R.D., Kumwenda N., Hoover D.R.et al. Human immunodeficiency virus load in breast milk, mastitis, and mother-to-child transmission of human immunodeficiency virus type 1. J Infect Dis. 180:1999;93-98.
33. Fawzi W.W., Msamanga G.I., Spiegelman D.et al. Randomised trial of effects of vitamin supplements on pregnancy outcomes and T cell counts in HIV-1-infected women in Tanzania. Lancet. 351:1998;1477-1482.
34. Wabwire-Mangen F., Gray R.H., Mmiro F.A.et al. Placental membrane inflammation and risks of maternal-to-child transmission of HIV-1 in Uganda. J Acquir Immune Defic Syndr. 22:1999;379-385.
35. Katzenstein D.A., Mbizvo M., Zijenah L.et al. Serum level of maternal human immunodeficiency virus (HIV) RNA, mortality, and vertical transmission of HIV in Zimbabwe. J Infect Dis. 179:1999;1382-1387.
36. Mofenson L.M., Lambert J.S., Stiehm E.R.et al. Risk factors for perinatal transmission of human immunodeficiency virus type 1 in women treated with zidovudine. N Engl J Med. 341:1999;385-393.
37. Maiques-Montesinos V., Cervera-Sanchez J., Bellver-Pradas J.et al. Post-cesarean section morbidity in HIV-positive women. Acta Obstet Gynecol Scand. 78:1999;789-792.
38. Grubert T.A., Reindell D., Kästner R., Lutz-Friedrich R., Belohradsky B.H., Dathe O. Complications after caesarean section in HIV-1-infected women not taking antiretroviral treatment. Lancet. 354:1999;1612-1613.
39. Bulterys M., Chao A., Dushimimana A., Saah A. Fatal complications after Caesarian section in HIV-infected women. AIDS. 10:1996;923-924.
40. Leroy V., Newell M.-L., Dabis F.et al. International multicentre pooled analysis of late postnatal mother-to-child transmission of HIV-1 infection. Lancet. 352:1998;597-600.
41. Miotti P.G., Taha T.E.T., Kumwenda N.I.et al. HIV transmission through breastfeeding: a study in Malawi. JAMA. 282:1999;744-749.
42. Nduati R., John G., Mbori-Ngacha D.et al. Effect of breastfeeding and formula feeding on transmission of HIV-1: a randomized clinical trial. JAMA. 283:2000;1167-1174.
43. Tess B.H., Rodriguez L.C., Newell M.-L.et al. Infant feeding and risk of mother-to-child transmission of HIV-1 in Sao Paulo State, Brazil. J Acquir Immune Defic Syndr. 19:1998;189-194.
44. Coutsoudis A., Pillay K., Spooner E.et al. Influence of infant-feeding patterns on early mother-to-child transmission of HIV-1 in Durban, South Africa: a prospective cohort study. Lancet. 354:1999;471-476.
45. Graham W.J., Newell M.-L. Seizing the opportunity: collaborative initiatives to reduce HIV and maternal mortality. Lancet. 353:1999;836-839.
46. Cartoux M., Meda N., Van de Perre P.et al. Acceptability of voluntary HIV testing by pregnant women in developing countries: an international survey. AIDS. 12:1998;2489-2493.
47. Ramon R., La Ruche G., Sylla-Koko F.et al. HIV counseling and testing: behavior and practices of women of childbearing age in Abidjan, Côte d'Ivoire. J Acquir Immune Defic Syndr. 17:1998;470-476.
48. Cartoux M., Msellati P., Meda N.et al. Attitude of pregnant women toward HIV testing in Abidjan, Côte d'Ivoire and Bobo-Dioulasso, Burkina Faso. AIDS. 12:1998;2337-2344.
49. Downing R.G., Otten R.A., Marum E.et al. Optimizing the delivery of HIV counseling and testing services: the Uganda experience using rapid HIV antibody test algorithms. J Acquir Immune Defic Syndr. 18:1998;384-388.
50. Bath GJ, McKenna S, Terunuma H, et al. Same day HIV voluntary counseling and testing improves overall acceptability among prenatal women in Zambia. XII World AIDS Conference. Geneva, June-July, 1998 (abstr 33282).
51. Soderlund N., Zwi K., Kinghorn A., Gray G. Prevention of vertical transmission of HIV: analysis of cost effectiveness of options available in South Africa. BMJ. 318:1999;1650-1656.
52. Thaineau V, Sirinirund P, Natpratan C. Going to scale: provision of modified short course AZT to all HIV-infected mothers and infants in northern Thailand, 1997-99. 2nd Conference on Global Strategies for the Prevention of HIV Transmission from Mothers to Infants. Montreal, September, 1999 (abstr 233).